GH Research PLC(GHRS)Earnings, Financials & Key Ratios
GHRS•NASDAQ
Price updated Jun 19, 2026
AboutGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$60M-20.7%
- Net Income-$48M-23.9%
- EPS (Diluted)-0.79-5.3%
- ROE-21.04%-7.5%
GHRS Key Insights
GH Research PLC (GHRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Profits declining 155.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 17.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GHRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GHRS Price & Volume
GH Research PLC (GHRS) stock price & volume — 10-year historical chart
Loading chart...
GHRS Growth Metrics
GH Research PLC (GHRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-33.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-16.46%
Return on Capital
10 Years-26.24%
5 Years-18.3%
3 Years-23.07%
Last Year-26.43%
GHRS Recent Earnings
GH Research PLC (GHRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.31-14.8%
$0.27
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.23+20.7%
$0.29
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.23+0.0%
$0.23
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.31vs $0.27-14.8% | — |
| Q2 2026 | Mar 5, 2026 | $0.23vs $0.29+20.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.23vs $0.23+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.22+31.8% | — |
Based on last 12 quarters of dataView full earnings history →
GHRS Peer Comparison
GH Research PLC (GHRS) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare GHRS vs Peers
GH Research PLC (GHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GHRS Income Statement
GH Research PLC (GHRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 335K | 268K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -335K▲ 0% | -268K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 310K | 446K | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M | 66.42M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 14K | 108K | 6.54M | 10.06M | 11.12M | 15M | 21.61M | 23.07M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 296K | 338K | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M | 43.27M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 5K | 14K | 280K | 294K | 0 | 75K |
Operating Income | -310K▲ 0% | -446K▼ 43.9% | -15.1M▼ 3285.7% | -30.55M▼ 102.3% | -41.22M▼ 34.9% | -50.31M▼ 22.1% | -60.68M▼ 20.6% | -66.69M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -43.87% | -3285.65% | -102.34% | -34.92% | -22.05% | -20.6% | - |
EBITDA | 0 | 0 | -15.08M | -30.51M | -40.91M | -50M | -60.34M | -66.34M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | -102.29% | -34.09% | -22.22% | -20.69% | -29.55% |
D&A (Non-Cash Add-back) | 310K | 446K | 19K | 47K | 315K | 315K | 335K | 350K |
EBIT | -310K | -446K | -9.19M | -22.46M | -35.52M | -38.91M | -60.68M | -58.73M |
Net Interest Income | 0 | 0 | -8.99K | 0 | 1.17M | 1.91M | 2.16M | 1.96M |
Interest Income | 0 | 0 | 9 | - | 1.89M | 2.63M | 2.63M | 2.32M |
Interest Expense | 0 | 0 | 9K | - | 723K | 717K | 463K | 369K |
Other Income/Expense | 0 | 0 | 5.9M | 8.1M | 5.63M | 11.35M | 12.42M | 10.27M |
Pretax Income | -310K▲ 0% | -446K▼ 43.9% | -9.2M▼ 1963.2% | -22.46M▼ 144.0% | -35.59M▼ 58.5% | -38.96M▼ 9.5% | -48.26M▼ 23.9% | -56.41M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -310K▲ 0% | -446K▼ 43.9% | -9.2M▼ 1963.2% | -22.46M▼ 144.0% | -35.59M▼ 58.5% | -38.96M▼ 9.5% | -48.26M▼ 23.9% | -56.41M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -43.87% | -1963.23% | -144.03% | -58.47% | -9.48% | -23.86% | -33.98% |
Net Income (Continuing) | -310K | -446K | -9.2M | -22.46M | -35.59M | -38.96M | -48.26M | -56.41M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -0.01▼ 32.4% | -0.18▼ 1124.5% | -0.14▲ 22.2% | -0.68▼ 385.7% | -0.75▼ 10.3% | -0.79▼ 5.3% | -0.91▲ 0% |
EPS Growth % | - | -32.43% | -1124.49% | 22.22% | -385.71% | -10.29% | -5.33% | -16.46% |
EPS (Basic) | -0.01 | -0.01 | -0.18 | -0.14 | -0.68 | -0.75 | -0.79 | - |
Diluted Shares Outstanding | 28M | 30.37M | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M | 62.03M |
Basic Shares Outstanding | 28M | 30.37M | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M | 62.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GHRS Balance Sheet
GH Research PLC (GHRS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 504K | 5.91M | 279.84M | 168.54M | 164.09M | 154.22M | 285.98M | 272.23M |
Cash & Short-Term Investments | 498K | 5.89M | 276.78M | 165.96M | 161.56M | 149.32M | 280.71M | 267.32M |
Cash Only | 498K | 5.89M | 276.78M | 165.96M | 78.42M | 100.79M | 246.25M | 242.65M |
Short-Term Investments | 0 | 0 | 0 | 0 | 83.14M | 48.53M | 34.46M | 24.67M |
Accounts Receivable | 0 | 0 | 48K | 90K | 178K | 1.73M | 1.29M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | -6K | 3.01M | -90K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 6K | 11K | 10K | 47K | 119K | 0 | 0 | 4.91M |
Total Non-Current Assets | 0 | 0 | 82K | 85.82M | 62.21M | 34.05M | 2.25M | 3.04M |
Property, Plant & Equipment | 0 | 0 | 82K | 97K | 1.07M | 748K | 620K | 580K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 85.72M | 61.14M | 33.3M | 0 | 22.53M |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.63M | 2.46M |
Total Assets | 504K▲ 0% | 5.91M▲ 1073.0% | 279.92M▲ 4634.8% | 254.36M▼ 9.1% | 226.3M▼ 11.0% | 188.27M▼ 16.8% | 288.23M▲ 53.1% | 275.27M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 1073.02% | 4634.84% | -9.13% | -11.03% | -16.8% | 53.09% | 141.73% |
Total Current Liabilities | 104K | 246K | 2.75M | 4.55M | 6.7M | 8.95M | 8.38M | 11.81M |
Accounts Payable | 93K | 1K | 883K | 1.87M | 0 | 0 | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | 2.48K |
Short-Term Debt | 0 | 0 | 0 | 0 | 343K | 255K | 365K | 357K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 168K | 312K | 6.36M | 8.7M | 8.02M | 11.46M |
Current Ratio | 4.85x | 24.03x | 101.80x | 37.07x | 24.49x | 17.23x | 34.13x | 23.04x |
Quick Ratio | 4.85x | 24.06x | 100.70x | 37.09x | 24.49x | 17.23x | 34.13x | 23.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 1.87M | 631K | 369K | 147K | 75K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 631K | 369K | 147K | 722K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 104K | 246K | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M | 11.89M |
Total Debt | 0 | 0 | 0 | 0 | 974K | 624K | 512K | 432K |
Net Debt | -498K | -5.89M | -276.78M | -165.96M | -77.45M | -100.17M | -245.74M | -242.22M |
Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 3.65x |
Interest Coverage | - | - | -1021.44x | - | -49.13x | -54.27x | -131.05x | -159.15x |
Total Equity | 400K▲ 0% | 5.67M▲ 1316.5% | 277.18M▲ 4791.9% | 249.82M▼ 9.9% | 218.97M▼ 12.3% | 178.95M▼ 18.3% | 279.7M▲ 56.3% | 263.38M▲ 0% |
Equity Growth % | - | 1316.5% | 4791.9% | -9.87% | -12.35% | -18.28% | 56.3% | 147.68% |
Book Value per Share | 0.01 | 0.19 | 5.33 | 4.80 | 4.21 | 3.44 | 4.58 | 4.25 |
Total Shareholders' Equity | 400K | 5.67M | 277.18M | 249.82M | 218.97M | 178.95M | 279.7M | 263.38M |
Common Stock | 801K | 871K | 1.3M | 1.3M | 1.3M | 1.3M | 1.55M | 1.55M |
Retained Earnings | -389K | -835K | -10.04M | -32.49M | -67.94M | -106.45M | -154.43M | -173.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -12K | 200K | -5.54M | -10.44M | -5.86M | -7.37M | 1.52M | 3.92M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GHRS Cash Flow Statement
GH Research PLC (GHRS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -289K | -330K | -15.28M | -26.2M | -33.34M | -42.28M | -43.55M | -46.33M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -14.19% | -4531.21% | -71.43% | -27.24% | -26.84% | -3% | -49.37% |
Net Income | -310K | -446K | -9.2M | -22.46M | -35.59M | -38.96M | -48.26M | -56.41M |
Depreciation & Amortization | 0 | 0 | 19K | 47K | 315K | 315K | 335K | 350K |
Stock-Based Compensation | 0 | 0 | 366K | 1.67M | 2.29M | 1.17M | 0 | 1.88M |
Deferred Taxes | 0 | 0 | -5.92M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 0 | 9K | -7.62M | -2M | -5M | 7.46M | 8.35M |
Working Capital Changes | 21K | 116K | -559K | 2.16M | 1.65M | 188K | -3.09M | -495.64K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | 0 | 0 | -104K | -84.69M | -54.1M | 65.14M | 46.17M | 43.35M |
Capital Expenditures | 0 | 0 | -104K | -67K | -100K | -49K | -121K | -181.35K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20.34M |
Cash from Financing | 797K | 5.5M | 286.45M | 0 | -204K | -304K | 139.65M | -2.23M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | -219K | -304K | 0 | -63K |
Equity Issued (Net) | 797K | 5.5M | 309.2M | 0 | 15K | 0 | 139.85M | 3.43M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -22.75M | 0 | 0 | 0 | -197K | -5.6M |
Net Change in Cash | 498K▲ 0% | 5.4M▲ 983.7% | 270.88M▲ 4919.1% | -110.82M▼ 140.9% | -87.53M▲ 21.0% | 22.37M▲ 125.6% | 145.46M▲ 550.2% | -2.3M▲ 0% |
Free Cash Flow | -289K▲ 0% | -330K▼ 14.2% | -15.39M▼ 4562.7% | -26.27M▼ 70.7% | -33.44M▼ 27.3% | -42.33M▼ 26.6% | -43.67M▼ 3.2% | -46.51M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -14.19% | -4562.73% | -70.7% | -27.3% | -26.61% | -3.16% | -12.62% |
FCF per Share | -0.01 | -0.01 | -0.30 | -0.50 | -0.64 | -0.81 | -0.72 | -0.75 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.74x | 1.66x | 1.17x | 0.94x | 1.09x | 0.90x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GHRS Key Ratios
GH Research PLC (GHRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -14.7% | -6.51% | -8.52% | -15.18% | -19.58% | -21.04% | -19.83% |
Return on Invested Capital (ROIC) | - | -13323.53% | -54.39% | -27.43% | -34.26% | -80.72% | -135.73% |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
Interest Coverage | - | -1021.44x | - | -49.13x | -54.27x | -131.05x | -159.15x |
FCF Conversion | 0.74x | 1.66x | 1.17x | 0.94x | 1.09x | 0.90x | 0.82x |
Related:GHRS Dividend History·GHRS Revenue History·GHRS Price History·GHRS P/E History·GHRS Financial Ratios·GHRS Institutional Holders
GHRS Frequently Asked Questions
GH Research PLC (GHRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GH Research PLC (GHRS) grew revenue by 0.0% over the past year. Growth has been modest.
GH Research PLC (GHRS) reported a net loss of $56.4M for fiscal year 2025.
Dividend & Returns
GH Research PLC (GHRS) has a return on equity (ROE) of -21.0%. Negative ROE indicates the company is unprofitable.
GH Research PLC (GHRS) had negative free cash flow of $46.5M in fiscal year 2025, likely due to heavy capital investments.